Successful allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning in a patient with severe aplastic anemia and active infection  by Wang, Tso-Fu et al.
lable at ScienceDirect
Tzu Chi Medical Journal 23 (2011) 100e102Contents lists avaiTzu Chi Medical Journal
journal homepage: www.tzuchimedjnl .comCase Report
Successful allogeneic peripheral blood stem cell transplantation with reduced
intensity conditioning in a patient with severe aplastic anemia and active
infection
Tso-Fu Wang a,b, Yi-Feng Wu a, Yu-Huai Ho c, Shih-Che Huang b,d, Sung-Chao Chu a, Ruey-Ho Kao a,b,*
aDepartment of Hematology and Oncology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
bDepartment of Medicine, College of Medicine, Tzu Chi University, Hualien, Taiwan
cDepartment of Infection, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
dDepartment of Gastroenterology, Buddhist Tzu Chi General Hospital, Hualien, Taiwana r t i c l e i n f o
Article history:
Received 11 January 2011
Received in revised form
16 February 2011
Accepted 2 March 2011
Key words:
Hematopoietic stem cell transplantation
Infection
Reduced intensity conditioning
Severe aplastic anemia* Corresponding author. Department of Hematology
Chi General Hospital, 707, Section 3, Chung-Yang Road
3 856 1825x2228; fax: þ886 3 857 7161.
E-mail address: rueyhokao@tzuchi.com.tw (R.-H. K
1016-3190/$ e see front matter Copyright  2011, Bu
doi:10.1016/j.tcmj.2011.03.006a b s t r a c t
Infection is the major cause of mortality in patients with severe aplastic anemia (SAA) and often results in
postponement of immunotherapy or transplantation treatment. We report on a 23-year-old man with
very SAA with almost no neutrophils who was primarily treated with peripheral blood stem cell
transplantation from an HLA-identical sibling. He received reduced dose conditioning with cyclophos-
phamide and antithymocyte globulin during active infection with typhlitis and pneumonia. Cyclophos-
phamide 50 mg/kg/d was given on Day 4 and Day 3 before transplantation and antithymocyte globulin
Fresenius 20 mg/kg/d was given on Day 3 and Day 2. Neutrophils and platelets were engrafted on
Day þ18 and Day þ20 after transplantation. Symptoms and signs of acute or chronic graft versus host
disease were not observed as of Day þ545 after transplantation. Allogeneic hematopoietic stem cell
transplantation with reduced intensity conditioning may be considered as the primary therapy for SAA
complicated by severe infection.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
All rights reserved.1. Introduction
Severe aplastic anemia (SAA) is characterized by a failure of
blood cell production with a marked hypocellular bone marrow
resulting in cytopenia. Because neutropenia is inevitably present in
patients with SAA, infections are the major cause of morbidity and
mortality in these patients. Hematopoietic stem cell trans-
plantation (HSCT) is the curative approach for patients with SAA
but adequate infection control before the transplantation is rec-
ommended. In this report, we successfully completed allogeneic
peripheral blood stem cell transplantation (PBSCT) as the ﬁrst-line
therapy in a patient with very SAA with almost no neutrophils
during active infection with typhlitis and pneumonia.and Oncology, Buddhist Tzu
, Hualien, Taiwan. Tel.: þ886
ao).
ddhist Compassion Relief Tzu Chi2. Case report
A 23-year-old man presented with fever, hypotension, diffuse
petechiae, abdominal pain, hematuria, and tarry stools in 2007. He
was admitted to the intensive care unit under the impression of
septic shock and gastrointestinal bleeding. His hemogram showed
white blood cells 0.34103/mL, neutrophils 0%, hemoglobin 9.4 g/
dL, and platelets 5103/mL.
Abdominal computed tomography (CT) disclosed marked
intramural edema and mucosal wall thickening of the cecum and
terminal ileum indicating an active infectious process in the right
lower quadrant (RLQ) of the abdominal bowel loops. Typhlitis with
regional peritonitis was impressed. Two sets of blood cultures
revealed growth of Klebsiella pneumoniae.
Bone marrow aspiration and biopsy examination performed for
pancytopenia prolonged more than 2 weeks and both showed
marked hypocellularity (<10%). Identiﬁable causes of pancytopenia
were ruled out and he was diagnosed with very SAA. Although the
tarry stools improved after blood transfusion and supportive care,
the intermittent spiking fever up to 39.5C and abdominal pain
remained despite use of granulocyte colony-stimulating factorFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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nin, and ﬂuconazole) for 3 weeks. A gallium-67 scan to assess
inﬂammatory activity showed a focal area of increased uptake of
radioactivity in the right lower abdominal region in the peritoneum
on single photon emission CT images (Fig.1A) His condition became
stable after changing the antibiotics to tigecycline, ceftazidime, and
micafungin, but a low-grade fever around 38C remained. An
abdominal CT scan showed a persistent lesion in the RLQ of the
abdomen (Fig. 1B), and a newly developed active infection was
visible in the right lower lung. The spiking fever occurred again the
following week and chest radiography showed the patches had
progressed over the right upper and lower lung. A serologic test,
sputum analysis, and bronchoaveolar lavage yielded negative
results for pathogens, such as bacteria, Mycoplasma, Pneumocystis
carinii, Legionella, and cytomegalovirus. About 7 weeks after
admission, empirical treatment with amphotericin B with dose
escalation to 1 mg/kg was added to the broad-spectrum antibiotics
for the persistent spiking fever. Chest radiography showed slightly
improving lung patches (Fig. 1C) but the intermittent fever
remained. His white blood cells count was still less than 500/mL
with almost no neutrophils (0e2%), which did not improve with G-Fig. 1. (A) Gallium-67 scan for inﬂammatory activity reveals a focal area of increased uptake
peritonitis (SPECT/CT images). (B) Pelvic CT with contrast medium administration shows m
ography reveals patchy inﬁltrations in the right upper and lower lung ﬁelds. An air broncho
photon emission computed tomography.CSF therapy. Blood transfusions were required more than twice per
week to maintain his hemoglobin level higher than 8 g/dL and
platelet level greater than 20103/mL.
The patient’s 21-year-old human leukocyte antigen-identical
sister agreed to donate stem cells. The donor’s stem cells were was
mobilized with 10 mg/kg/d recombinant human G-CSF daily for 5
days by subcutaneous injection. Peripheral blood stem cells were
collected on the 5th day by continuous ﬂow blood cell apheresis. The
patientwas transferred to the transplantationward on the 51st day of
hospitalization and received conditioning with cyclophosphamide
(Cy) 50 mg/kg/d on Day 4 and Day 3 before transplantation and
antithymocyte globulin (ATG Fresenius) 20 mg/kg/d on Day 3 and
Day 2. The donor’s unmanipulated stem cells were infused, con-
taining 8.6106 CD34þ cells/kg of the patient’s weight. Cyclosporin
A (CsA) and short-term methotrexate were administered as graft-
versus-host disease (GVHD) prophylaxis. CsAwas administered from
1 day before transplantation and adjusted according to blood levels
(300e400 ng/mL). Methotrexate was injected intravenously at
a dose of 15 mg/m2 on Day þ1 after transplantation and 10 mg/m2
on Day þ3, Day þ6, and Day þ11 after transplantation. The patient
received 300 mg G-CSF per day from 1 day after transplantation untilof radioactivity in the right lower abdominal region, which is suspected to be regional
arked cecal wall thickening with pericolonic inﬂammatory stranding. (C) Chest radi-
gram is also noted in the upper lung ﬁeld. CT¼ computed tomography; SPECT¼ single
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stem cell infusion. The platelet count was maintained above
30103/mL with platelet transfusions on Day þ20. Fever subsided
after Day þ11 of transplantation. An abdominal CT scan on Day þ16
after transplantation showed persistent but resolving lesions in the
RLQ of the abdomen. The hospitalization course after trans-
plantationwas smooth anddonor origin engraftmentwas conﬁrmed
by polymerase chain reaction analysis of DNA short tandem repeats.
CT-guided biopsy of the right upper lung lesionwas performed after
full recovery of platelets and revealed aspergillosis infection. The
amphotericin B was discontinued at an accumulated dose of 2 g and
therapy was shifted to oral voriconazole after discharge.
CsA was then tapered and discontinued 6 months after trans-
plantation because there was no evidence of GVHD. No symptoms
or signs of chronic GVHD were noted at the latest follow-up at the
outpatient clinic as of Day þ545 after transplantation.
3. Discussion
SAA occasionally presents with life-threatening infection at
diagnosis but seldom can be treated with transplantation during
active infection. Bacterial and fungal infections are common causes
of morbidity and mortality in patients with SAA [1,2]. In patients
with active infections, broad-spectrum antibacterial and/or anti-
fungal agents are usually given to completely resolve the infection
before allogeneic HSCT is planned. Many patients succumb to
infections before HSCT and most of them die of sepsis from
pulmonary or abdominal infection. In those patients with infec-
tions who do undergo HSCT, the outcome is generally poor because
of infection-related mortality and an increased incidence of graft
rejection [3,4]. Although active fungal infection is not an absolute
contraindication for transplantation, the early mortality rate is
22e27% for patients with active fungal infection receiving HSCT
[5,6]. In this report, the patient successfully received allogeneic
HSCT as ﬁrst-line treatment of SAA during active infection with
typhlitis and pneumonia.
Because graft failure depends on residual host immunity, an
intense conditioning regimen for SAA patients undergoing trans-
plantation was previously thought to be important. This was
initially accomplished through the addition of total body irradia-
tion to conditioning chemotherapy. Conditioning regimens with
radiation indeed resulted in lower rates of graft failure [7] but were
also associated with signiﬁcant early and late toxicities [4,8,9]. The
necessity for total body irradiation was questioned after the
introduction of ATG in the conditioning regimen [10e12]. The use
of thoracoabdominal irradiation in combination with Cy was
associated with higher acute and chronic GVHD rates and lower
overall survival, compared with that seen with Cy and ATG [13].
Therefore, Cy plus ATG is the current standard for transplantation
conditioning for SAA [14]. Accumulating evidence from ﬂudar-
abine-containing conditioning regimens also shows that engraft-
ment does not absolutely depend on the intensity of the cytotoxic
drugs in conditioning [15,16]. However, in one study, clinically
signiﬁcant toxicity still occurred in conditioning in 21% of patients
with 6.9% mortality [17]. The United State Food and Drug Admin-
istration has not yet approved ﬂudarabine for use in conditioning
chemotherapy in transplantation in patients with SAA or acute
leukemia. In our patient, we reduced the Cy dose to half of the
conventional myeloablative-conditioning regimen in combination
with a two-thirds dose of ATG to avoid severe toxicity and used
PBSCT for potential faster engraftment. Although a number of
studies have shown that PBSCT is associated with a higher risk of
chronic GVHD, acute/chronic GVHD and overall mortality with
bone marrow and PBSC were comparable in patients older than 20years [18]. This patient had no major toxicity and survived severe
neutropenia with active infection. Fortunately, there were no signs
or symptoms of GVHD at the latest follow-up.
In conclusion, we report our experience with a patient with
newly diagnosed very SAA with almost no neutrophils who was
successfully treated with reduced intensity conditioning PBSCT as
the ﬁrst-line therapy during active infection. This suggests that
primaryallogeneic PBSCTwith a dose-reduced conditioning regimen
is safe and effective in the treatment of SAA with active infection.References
[1] Weinberger M, Elattar I, Marshall D, Steinberg SM, Redner RL, Young NS,
et al. Patterns of infection in patients with aplastic anemia and the emer-
gence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992;
71:24e43.
[2] Torres HA, Bodey GP, Rolston KV, Kantarjian HM, Raad II , Kontoyiannis DP.
Infections in patients with aplastic anemia: experience at a tertiary care
cancer center. Cancer 2003;98:86e93.
[3] Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of
aplastic anemia. An analysis of factors associated with graft rejection. N Engl J
Med 1977;296:61e6.
[4] Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE,
Gale RP, et al. Graft failure following bone marrow transplantation for severe
aplastic anemia: risk factors and treatment results. Blood 1989;73:606e13.
[5] Aki ZS, Sucak GT, Yegin ZA, Guzel O, Erbas G, Senol E. Hematopoietic stem cell
transplantation in patients with active fungal infection: not a contraindication
for transplantation. Transplant Proc 2008;40:1579e85.
[6] George B, Mathews V, Viswabandya A, Srivastava A, Chandy M. Fludarabine-
based reduced intensity conditioning regimens for allogeneic hematopoietic
stem cell transplantation in patients with aplastic anemia and fungal infec-
tions. Clin Transplant 2009;23:228e32.
[7] Gale RP, Ho W, Feig S, Champlin R, Tesler A, Arenson E, et al. Prevention of
graft rejection following bone marrow transplantation. Blood 1981;57:9e12.
[8] Gluckman E, Horowitz MM, Champlin RE, Hows JM, Bacigalupo A, Biggs JC,
et al. Bone marrow transplantation for severe aplastic anemia: inﬂuence of
conditioning and graft-versus-host disease prophylaxis regimens on outcome.
Blood 1992;79:269e75.
[9] Deeg HJ, Socie G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A, et al.
Malignancies after marrow transplantation for aplastic anemia and fanconi
anemia: a joint Seattle and Paris analysis of results in 700 p.tients. Blood 1996;
87:386e92.
[10] Smith BR, Guinan EC, Parkman R, Ferrara J, Levey RH, Nathan DG, et al. Efﬁcacy
of a cyclophosphamide-procarbazine-antithymocyte serum regimen for
prevention of graft rejection following bone marrow transplantation for
transfused patients with aplastic anemia. Transplantation 1985;39:671e3.
[11] Storb R, Weiden PL, Sullivan KM, Appelbaum FR, Beatty P, Buckner CD, et al.
Second marrow transplants in patients with aplastic anemia rejecting the ﬁrst
graft: use of a conditioning regimen including cyclophosphamide and
antithymocyte globulin. Blood 1987;70:116e21.
[12] Deeg HJ, Amylon ID, Harris RE, Collins R, Beatty PG, Feig S, et al. Marrow
transplants from unrelated donors for patients with aplastic anemia:
minimum effective dose of total body irradiation. Biol Blood Marrow Trans-
plant 2001;7:208e15.
[13] Ades L, Mary JY, Robin M, Ferry C, Porcher R, Esperou H, et al. Long-term
outcome after bone marrow transplantation for severe aplastic anemia. Blood
2004;103:2490e7.
[14] Kahl C, Leisenring W, Deeg HJ, Chauncey TR, Flowers ME, Martin PJ, et al.
Cyclophosphamide and antithymocyte globulin as a conditioning regimen for
allogeneic marrow transplantation in patients with aplastic anaemia: a long-
term follow-up. Br J Haematol 2005;130:747e51.
[15] Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socie G, Maury S, et al. Fludar-
abine, cyclophosphamide and anti-thymocyte globulin for alternative donor
transplants in acquired severe aplastic anemia: a report from the EBMT-SAA
Working Party. Bone Marrow Transplant 2005;36:947e50.
[16] Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Socie G, et al. Improved
outcome of patients older than 30 years receiving HLA-identical sibling
hematopoietic stem cell transplantation for severe acquired aplastic anemia
using ﬂudarabine-based conditioning: a comparison with conventional
conditioning regimen. Haematologica 2009;94:1312e5.
[17] Deeg HJ, O'Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA, et al. Optimization
of conditioning for marrow transplantation from unrelated donors for
patients with aplastic anemia after failure of immunosuppressive therapy.
Blood 2006;108:1485e91.
[18] Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN,
Bullorsky E, et al. Worse outcome and more chronic GVHD with peripheral
blood progenitor cells than bone marrow in HLA-matched sibling donor
transplants for young patients with severe acquired aplastic anemia. Blood
2007;110:1397e400.
